Celgene, Nurix Collaborate For $150m Up Front
This article was originally published in Scrip
Celgene will pay Nurix Inc. $150m up front to develop and commercialize novel small molecules that modulate the ubiquitin proteasome system (UPS) in a deal that gives both companies multiple options for benefitting from joint oncology, inflammation and immunology programs.
You may also be interested in...
Nurix’s $120m Venture Round Will Bring Two Protein-Modulating Therapies To Clinic
Company’s technology harnesses E3 ligases to either degrade dysregulated proteins or inhibit a specific ligase to increase substrate protein levels for therapeutic benefit.
VC Roundup: Cleave Raises $37m To Maintain Phase I Momentum, Plus $233.5m In Recent Financings
Cleave Biosciences leads off a recent slate of venture capital financings with $37m to fund ongoing Phase I programs for the lead drug from its protein homeostasis-focused platform.
Building On Successes During Turbulent Times, SR One Closes $600m Fund II
SR One will keep investing in a mix of new companies, early-stage firms and later opportunities with its second fund, raised even as biotech continues to endure challenging financial times.